|
Assay | LTA | MEA | VerifyNow P2Y12 | VASP | Impact-R | PFA 100 INNOVANCE | Platelet works |
|
Measurement | Aggregation | Aggregation | Aggregation | Activation | Adhesion/aggregation | Aggregation | Aggregation |
Specimen type | Platelet-rich plasma | Whole blood | Whole blood | Whole blood | Whole blood | Whole blood | Whole blood |
Standard conditions | Variable ADP concentration | Variable ADP concentration | Fixed ADP and PGE1 | Fixed ADP and PGE1 | Recommended ADP | Fixed PGE1 | Recommended ADP |
Technical skills required | Specialized lab and personnel | Specialized lab and personnel | None | Specialized lab and personnel | Specialized lab and personnel | None | None |
Advantages | Well-studied tied to clinical outcomes | Physiologic environment Minimal sample manipulation | User-friendly and fast No sample processing | P2Y12 receptor-specific Small blood volume required | User-friendly and fast Small blood volume required | User-friendly and fast Small blood volume required | Fast |
Disadvantages | Time and extent of processing lack of standardization | Less clinical evidence with assay smaller range for response | Unadjustable agonist concentration expensive | Measures earlier marker (signaling) | Limited experience with assay | Result dependent on von Willebrand factor levels and hematocrit | Time dependent Not well studied |
|